817 related articles for article (PubMed ID: 26851604)
21. The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey.
Armour M; Lawson K; Wood A; Smith CA; Abbott J
PLoS One; 2019; 14(10):e0223316. PubMed ID: 31600241
[TBL] [Abstract][Full Text] [Related]
22. Costs of endometriosis in Austria: a survey of direct and indirect costs.
Prast J; Oppelt P; Shamiyeh A; Shebl O; Brandes I; Haas D
Arch Gynecol Obstet; 2013 Sep; 288(3):569-76. PubMed ID: 23503974
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.
Nellesen D; Yee K; Chawla A; Lewis BE; Carson RT
J Manag Care Pharm; 2013; 19(9):755-64. PubMed ID: 24156644
[TBL] [Abstract][Full Text] [Related]
24. Indirect costs associated with ulcerative colitis: a systematic literature review of real-world data.
Constantin J; Atanasov P; Wirth D; Borsi A
BMC Gastroenterol; 2019 Nov; 19(1):179. PubMed ID: 31706270
[TBL] [Abstract][Full Text] [Related]
25. Expert panel on practice patterns in the management of cow's milk protein allergy and associated economic burden of disease on health service in Turkey.
Sekerel BE; Seyhun O
J Med Econ; 2017 Sep; 20(9):923-930. PubMed ID: 28602101
[TBL] [Abstract][Full Text] [Related]
26. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not?
Vercellini P; Bandini V; Buggio L; Barbara G; Berlanda N; Dridi D; Frattaruolo MP; Somigliana E
Hum Reprod Open; 2023; 2023(2):hoad008. PubMed ID: 37016694
[TBL] [Abstract][Full Text] [Related]
27. The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.
Malinowski KP; Kawalec P
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):285-300. PubMed ID: 25579502
[TBL] [Abstract][Full Text] [Related]
28. The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review.
Iragorri N; de Oliveira C; Fitzgerald N; Essue B
Appl Health Econ Health Policy; 2021 May; 19(3):325-341. PubMed ID: 33368032
[TBL] [Abstract][Full Text] [Related]
29. Systematic review of cost-of-illness studies in hand eczema.
Politiek K; Oosterhaven JA; Vermeulen KM; Schuttelaar ML
Contact Dermatitis; 2016 Aug; 75(2):67-76. PubMed ID: 27218305
[TBL] [Abstract][Full Text] [Related]
30. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies.
Xie F; Kovic B; Jin X; He X; Wang M; Silvestre C
Pharmacoeconomics; 2016 Nov; 34(11):1087-1100. PubMed ID: 27339668
[TBL] [Abstract][Full Text] [Related]
31. Global Economic Impact of Dental Diseases.
Listl S; Galloway J; Mossey PA; Marcenes W
J Dent Res; 2015 Oct; 94(10):1355-61. PubMed ID: 26318590
[TBL] [Abstract][Full Text] [Related]
32. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Franklin M; Pollard D; Sah J; Rayner A; Sun Y; Dube F; Sutton A; Qin L
Adv Ther; 2024 Jul; 41(7):2700-2722. PubMed ID: 38833143
[TBL] [Abstract][Full Text] [Related]
33. Consensus on Recording Deep Endometriosis Surgery: the CORDES statement.
Vanhie A; Meuleman C; Tomassetti C; Timmerman D; D'Hoore A; Wolthuis A; Van Cleynenbreugel B; Dancet E; Van den Broeck U; Tsaltas J; Renner SP; Ebert AD; Carmona F; Abbott J; Stepniewska A; Taylor H; Saridogan E; Mueller M; Keckstein J; Pluchino N; Janik G; Zupi E; Minelli L; Cooper M; Dunselman G; Koh C; Abrao MS; Chapron C; D'Hooghe T
Hum Reprod; 2016 Jun; 31(6):1219-23. PubMed ID: 27094477
[TBL] [Abstract][Full Text] [Related]
34. Economic burden of multiple sclerosis in the United States: A systematic literature review.
Schauf M; Chinthapatla H; Dimri S; Li E; Hartung DM
J Manag Care Spec Pharm; 2023 Dec; 29(12):1354-1368. PubMed ID: 37976077
[TBL] [Abstract][Full Text] [Related]
35. Productivity loss due to overweight and obesity: a systematic review of indirect costs.
Goettler A; Grosse A; Sonntag D
BMJ Open; 2017 Oct; 7(10):e014632. PubMed ID: 28982806
[TBL] [Abstract][Full Text] [Related]
36. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
37. The economic burden of systemic sclerosis-A systematic review.
Chen Y; Wu L; J Hernández-Muñoz J; J Miller M; Pope M; Huyan Y; Zhong L
Int J Rheum Dis; 2022 Feb; 25(2):110-120. PubMed ID: 34970861
[TBL] [Abstract][Full Text] [Related]
38. [Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].
Wrona W; Hermanowski T; Golicki D; Jakubczyk M; Macioch T; Goszczyńska K; Wójcik R
Przegl Epidemiol; 2011; 65(1):147-52. PubMed ID: 21735852
[TBL] [Abstract][Full Text] [Related]
39. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States.
Patel JG; Nagar SP; Dalal AA
Int J Chron Obstruct Pulmon Dis; 2014; 9():289-300. PubMed ID: 24672234
[TBL] [Abstract][Full Text] [Related]
40. The cost burden of multiple sclerosis in the United States: a systematic review of the literature.
Adelman G; Rane SG; Villa KF
J Med Econ; 2013; 16(5):639-47. PubMed ID: 23425293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
